CN110022881B - Cd73介导的免疫抑制的抑制剂 - Google Patents

Cd73介导的免疫抑制的抑制剂 Download PDF

Info

Publication number
CN110022881B
CN110022881B CN201780071772.6A CN201780071772A CN110022881B CN 110022881 B CN110022881 B CN 110022881B CN 201780071772 A CN201780071772 A CN 201780071772A CN 110022881 B CN110022881 B CN 110022881B
Authority
CN
China
Prior art keywords
cancer
compound
alkyl
group
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780071772.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110022881A (zh
Inventor
J·卡利夏克
K·V·劳森
M·R·莱莱蒂
E·A·林德赛
D·H·迈尔斯
E·纽科姆
J·P·帕沃尔斯
E·U·谢里夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcus Biosciences Inc
Original Assignee
Arcus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences Inc filed Critical Arcus Biosciences Inc
Publication of CN110022881A publication Critical patent/CN110022881A/zh
Application granted granted Critical
Publication of CN110022881B publication Critical patent/CN110022881B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
CN201780071772.6A 2016-11-18 2017-11-17 Cd73介导的免疫抑制的抑制剂 Active CN110022881B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662424241P 2016-11-18 2016-11-18
US62/424,241 2016-11-18
PCT/US2017/062166 WO2018094148A1 (en) 2016-11-18 2017-11-17 Inhibitors of cd73-mediated immunosuppression

Publications (2)

Publication Number Publication Date
CN110022881A CN110022881A (zh) 2019-07-16
CN110022881B true CN110022881B (zh) 2023-05-02

Family

ID=62145728

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780071772.6A Active CN110022881B (zh) 2016-11-18 2017-11-17 Cd73介导的免疫抑制的抑制剂

Country Status (6)

Country Link
US (1) US11267845B2 (https=)
EP (1) EP3541396A4 (https=)
JP (1) JP7150712B2 (https=)
CN (1) CN110022881B (https=)
TW (1) TWI786072B (https=)
WO (1) WO2018094148A1 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3541396A4 (en) 2016-11-18 2020-07-22 Arcus Biosciences, Inc. CD73-MEDIATED IMMUNOSUPPRESSION INHIBITORS
CN110382544B (zh) 2017-03-16 2023-12-22 先天制药公司 用于治疗癌症的组合物和方法
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
WO2019068907A1 (en) 2017-10-06 2019-04-11 Innate Pharma RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
JP7417530B2 (ja) 2018-03-09 2024-01-18 アーカス バイオサイエンシズ インコーポレイティド 優先投与される免疫増強薬
CN112423764A (zh) 2018-04-30 2021-02-26 欧瑞克制药公司 Cd73抑制剂
EP3810109B1 (en) 2018-05-31 2024-08-07 Peloton Therapeutics, Inc. Compounds and compositions for inhibiting cd73
MX2020012107A (es) 2018-06-18 2021-01-29 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
US11332492B2 (en) 2018-08-28 2022-05-17 Jiangsu Hengrui Medicine Co., Ltd. CD73 inhibitors and therapeutic uses thereof
CN110885352B (zh) * 2018-09-11 2023-02-24 润佳（苏州）医药科技有限公司 Cd73抑制剂及其药学应用
US11530234B2 (en) 2018-09-11 2022-12-20 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 inhibitors and pharmaceutical uses thereof
US10881681B2 (en) 2018-09-11 2021-01-05 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 inhibitors and pharmaceutical uses thereof
US20200345725A1 (en) 2019-01-11 2020-11-05 Omeros Corporation Methods and Compositions for Treating Cancer
CN112955444B (zh) * 2019-01-22 2023-12-12 江苏恒瑞医药股份有限公司 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
US12310965B2 (en) 2019-03-29 2025-05-27 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
HUE072504T2 (hu) 2019-10-30 2025-11-28 Oric Pharmaceuticals Inc CD73-inhibitorok
CN115298165B (zh) 2020-03-19 2024-09-17 艾库斯生物科学有限公司 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物
BR112022024221A2 (pt) 2020-06-02 2022-12-20 Arcus Biosciences Inc Anticorpos para tigit
EP4251633A4 (en) * 2020-11-25 2024-09-25 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF
JP2024521712A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ阻害化合物
CN117295741A (zh) 2021-05-21 2023-12-26 艾库斯生物科学有限公司 Axl化合物
WO2023077046A1 (en) 2021-10-29 2023-05-04 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
CA3256561A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and their uses
JP2025520300A (ja) * 2022-06-17 2025-07-03 上海森輝医薬有限公司 シクロペンチルアデノシン誘導体及びその医薬的使用
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
US20260028336A1 (en) 2022-07-20 2026-01-29 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
CN119768155A (zh) 2022-09-14 2025-04-04 艾库斯生物科学有限公司 依曲地南的分散体
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
EP4705292A1 (en) 2023-05-05 2026-03-11 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
CN116298323B (zh) * 2023-05-16 2023-08-22 南京联笃生物科技有限公司 一种用于诊断狼疮性肾炎的生物标志物及应用
US20250011318A1 (en) 2023-05-25 2025-01-09 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit
WO2025072330A1 (en) 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
WO2025076299A1 (en) 2023-10-06 2025-04-10 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
TW202523302A (zh) 2023-11-02 2025-06-16 美商阿克思生物科學有限公司 噻唑化合物及其使用方法
WO2025119278A1 (zh) * 2023-12-07 2025-06-12 无锡和誉生物医药科技有限公司 一种cd73抑制剂药物组合物，其制备方法和应用
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017803A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5700786A (en) * 1993-06-11 1997-12-23 Sloan-Kettering Institute For Cancer Research Analogues of adenosine 5'diphosphate and pharmaceutical compositions thereof
EP1860113A1 (en) * 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
WO2015164573A1 (en) * 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4118958B2 (ja) * 1996-10-09 2008-07-16 ファーマセット，リミティド テトラホスホネート二環式トリス無水物
US20110245088A1 (en) * 2010-04-05 2011-10-06 National Tsing Hua University Amide-based solution-phase derived library and method for screening thereof
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
HUE063388T2 (hu) * 2016-01-08 2024-01-28 Arcus Biosciences Inc Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása
EP3541396A4 (en) 2016-11-18 2020-07-22 Arcus Biosciences, Inc. CD73-MEDIATED IMMUNOSUPPRESSION INHIBITORS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
WO1994017803A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors
US5700786A (en) * 1993-06-11 1997-12-23 Sloan-Kettering Institute For Cancer Research Analogues of adenosine 5'diphosphate and pharmaceutical compositions thereof
EP1860113A1 (en) * 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
WO2015164573A1 (en) * 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A second target of benzamide riboside;Breton Roussel等;《Cancer Biology & Therapy》;20120906;第13卷(第13期);第1292页 *
Application of molecular topology to the prediction of the antimalarial activity of a group of uracil-based acyclic and deoxyuridine compounds;Ramon Garcia-Domenech等;《International Journal of Pharmaceutics》;20080715;第363卷;第80页表1 *
CAS RN: 736134-50-2;American Chemical Society;《STN Registry[online]》;20040831;第3-4页 *
Design and synthesis of phosphonoacetic acid (PPA) ester and amide bioisosters of ribofuranosylnucleo-side diphosphates as potential ribonucleotide reductase inhibitors and evaluation of their enzyme inhibitory, cytostatic and antiviral activity;Stefano Manfredini等;《Antiviral Chemistry & Chemotherapy》;20031231;第14卷;第191页 *
Synthesis and in vitro stability of nucleoside 5’-phosphonate derivatives;Silvia Vertuani等;《European Journal of Medicinal Chemistry》;20120515;第54卷;第204-205页 *
α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors;Sanjay Bhattarai等;《Journal of Medicinal Chemistry》;20150706;第58卷;第6248-6263页 *

Also Published As

Publication number Publication date
EP3541396A1 (en) 2019-09-25
JP7150712B2 (ja) 2022-10-11
JP2019535720A (ja) 2019-12-12
TW201822772A (zh) 2018-07-01
CN110022881A (zh) 2019-07-16
WO2018094148A1 (en) 2018-05-24
US20200062797A1 (en) 2020-02-27
US11267845B2 (en) 2022-03-08
TWI786072B (zh) 2022-12-11
EP3541396A4 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
CN110022881B (zh) Cd73介导的免疫抑制的抑制剂
US12459967B2 (en) Modulators of 5′-nucleotidase, ecto and the use thereof
US20240285665A1 (en) Inhibitors of adenosine 5'-nucleotidase
TWI850299B (zh) Cd73抑制劑之固體形式及其用途
HK40073403A (zh) 胞外5’-核苷酸酶的调节剂及其用途
HK40106303A (en) Modulators of 5'-nucleotidase, ecto and the use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant